Skip to content

2030 at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA

Other financials

Income statement

See full
Revenue$179.0K-50.6%
Gross profit$131.0K-56.3%
Operating income-$6.9M-16.2%
Net income-$4.2M+11.6%
EPS (diluted)-$0.08+57.9%

Balance sheet

See full
Cash & equivalents$30.5M-19.6%
Total debt$21.9M+995%
Total equity$75.4M-6.4%
Total assets$92.0M-14.9%

Cash flow

See full
Operating cash flow-$7.3M-128%
CapEx$6.0K
Free cash flow-$7.3M-128%

Valuation

See full
Market cap$170.56M+189%
P/S174×+93.5×

Profitability

See full
Gross margin71.9%
Operating margin-3,717.2%+1,952pp
Net margin-2,117.2%-517pp
FCF margin-2,064.1%

Returns & leverage

See full
Return on equity-26.6%-0.8pp
Debt / equity0.3×+0.2×
Current ratio3.2×-0.7×

Where this comes from

Reported directly by Rafael Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.

The official record: Rafael Holdings, Inc.’s 10-Q, filed June 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rafael Holdings, Inc.'s 2030.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rafael Holdings, Inc.'s 2030?
Rafael Holdings, Inc. (RFL) reported 2030 of $130K in Q1 2026.
How has Rafael Holdings, Inc.'s 2030 changed year-over-year?
Rafael Holdings, Inc.'s 2030 decreased by 0.0% year-over-year, from $130K to $130K.